Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial - Yuan, Guangwen; Zhang, Keqiang; Zheng, Hong; Wu, Yan; Sun, Haolin; Zhang, Jiajing; Sun, Xiyang; Wu, Lingying (Gynecologic oncology, 2024)
Keywords: Adult; Aged; Anti-VEGF antibody; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antitumor activities; Carcinoma, Ovarian Epithelial - drug therapy; Dose escalation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms - drug therapy; Fallopian Tube Neoplasms - pathology; Female; Hematology, Oncology, and Palliative Medicine; Humans; Middle Aged; Obstetrics and Gynecology; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Peritoneal Neoplasms - drug therapy; Platinum resistance; Progression-Free Survival; Suvemcitug; Topotecan - administration & dosage; Topotecan - adverse effects; Platinum resistance; Anti-VEGF antibody; Dose escalation; Ovarian cancer; Suvemcitug; Antitumor activities